e12703 Background: High-risk localized hormone receptor (HR)-positive, HER2-negative breast cancer is often treated with chemotherapy regardless of age. We evaluated whether chemotherapy improves survival in women ≥70 with high nodal burden. Methods: This is a retrospective cohort study using SEER plus database (2000–2022) from 17 registries. Women diagnosed with non-metastatic HR–positive, HER2-negative breast cancer and 4–9 positive lymph nodes between 2010 and 2021 were included. Patients were stratified by age and categorized based on receipt of chemotherapy. The primary outcome was breast cancer–specific survival (BCSS). Covariates included age, race, tumor grade, marital status, tumor T stage, and radiation therapy. Cox models assessed the association between chemotherapy and BCSS, including age interactions. Adjusted HRs with 95% CIs are reported and p ≤ 0.05 was significant. Results: Out of 4208 female patients, 57.6% received chemotherapy. Median BCSS was longer with chemotherapy (54 vs. 45 months, HR 0.64, 95% CI 0.45–0.58, p 80 1.12 (0.82–1.52) 0.47 1.72 (1.10–2.71) 0.018
Khalid et al. (Thu,) studied this question.